reconstitution comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | Thymosin beta-4 fragment; TB4 fragment | Naming is inconsistent across suppliers and publications |
| Reported sequence | Ac-LKKTETQ | Corresponds to residues 17-23 of the parent protein |
| Frequently cited registry number | 77591-33-4 | Associated with full-length thymosin beta-4 rather than the fragment |
| Common supplied form | Freeze-dried solid | Often presented as an acetate or trifluoroacetate salt |
| Regulatory treatment | Varies by country | Frequently handled as a research chemical; not broadly approved as a therapeutic |
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
Lyophilized peptide arrives as a dry cake that should stay sealed until use. Reconstitution is generally performed with sterile water or a buffered solution, and the resulting liquid should be handled gently to limit mechanical stress. Repeated freeze-thaw cycles are widely described as harmful to short peptides, so dividing a reconstituted batch into single-use portions is a common practice. Laboratories also record the solvent, concentration, and date of preparation on the vial label to keep later measurements traceable.
Dry powder is commonly held at minus twenty degrees Celsius, with some suppliers recommending lower temperatures for long-term archival storage. Once dissolved, solutions are typically kept cold and protected from light, since aqueous peptide solutions can lose integrity through hydrolysis or oxidation over time. Stability data specific to this fragment are limited in the public literature, and much of the guidance comes from general peptide handling practice rather than from controlled degradation studies. Users therefore treat stated shelf lives as approximate rather than fixed.
Identity and purity are normally assessed with reversed-phase high-performance liquid chromatography, paired with mass spectrometry to confirm molecular mass. A certificate of analysis reports a purity percentage, usually derived from chromatographic peak area, but that figure does not by itself prove a correct sequence or the absence of counterions. Independent verification may include amino acid analysis or peptide mapping. Batch-to-batch variation is a documented concern in the research chemical market, and the gap between a quoted purity value and actual peptide content can be substantial when the material is a salt or retains residual water.
TB-500 is a synthetic peptide whose sequence corresponds to a short fragment near the N-terminus of thymosin beta-4, a small protein present in most mammalian cells. The fragment is commonly cited as containing the actin-binding region of the parent molecule, which is why it appears in laboratory work on cell migration and tissue repair. Suppliers distribute it as a lyophilised powder intended for research use. Its identity is defined by amino acid sequence and by the presence of an acetyl group on the N-terminal residue.
Full-length thymosin beta-4 consists of roughly forty-three amino acids and ranks among the more abundant small proteins in the cytoplasm. The fragment is much shorter, so it cannot reproduce every function attributed to the intact molecule. In cell culture, short actin-binding motifs can interfere with filament dynamics and cell movement, but such observations come from controlled experiments rather than from whole-animal work. Whether a truncated fragment produces the same effects as the parent protein remains an open question.
Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.
== Other Activities == 1972–1975 – Associate Member, Viking Lander Science Team, NASA 1979–1982 – – Member, Committee on Response Strategies to Unusual Chemical Hazards, Assembly of Life Sciences, National Research Council 1982 – U.S. Coordinator, U.S.-Japan Joint Seminar on “Microcolumn Separation Methods and their Ancillary Techniques,” Honolulu, Hawaii 1980–1984 – Member, Advisory Committee to the Analytical Chemistry Division, Oak Ridge National Laboratory 1986 – Instructor, ACS Short Course on Supercritical Fluid Chromatography 1988, 1990 – Organizing Committee, International Symposium, “Microcolumn Separation Methods,” Bloomington, IN and Aronberg, Sweden 1988, 1991 – Scientific Committee, International Symposium, “HPLC 88” and “HPLC 92” 1977–Pres. – Instructor, ACS Short Course on Capillary Gas Chromatography 1978–Pres. – ACS Lecture Tour Speaker 1990–Pres. – Scientific Committee, International Symposia on Capillary Chromatography 1994 – Scientific Committee, Glycobiology: Analytical Methods 2003 – Member of the Center for the Integrative Study of Animal Behavior, Indiana University 2004 – Member of the Indiana University Cancer Center, IU School of Medicine .
The Second Collier Ministry was the 18th Ministry of the Government of Western Australia and was led by Labor Premier Philip Collier. It succeeded the Second Mitchell Ministry on 24 April 1933, following the defeat of the Nationalist government at the 1933 election on 8 April. The ministry was followed by the Willcock Ministry on 27 August 1936, a week after Collier resigned as Premier on the grounds of ill health and handed over to the Deputy Premier, John Willcock. The following ministers served until the reconstitution of the ministry on 26 March 1935:
On 17 September, at least 12 people were killed and more than 2,750 were wounded, including Hezbollah members and civilians, after the explosions of their pagers in Lebanon and Syria, including in Beirut. The attack resulted in 1,500 fighters being taken out of action, with many facing blindness or losing their hands. Among those injured was the Iranian ambassador, Mojtaba Amani. Several drones launched from Lebanon crossed the border. Hezbollah confirmed the death of 12 militants on that day. Also on 17 September, the Shin Bet claimed that it thwarted a Hezbollah attempt for assassinate a former senior defence official with a Claymore mine. On 18 September another series of explosions involving wireless devices was reported across Lebanon, killing at least 30 people and injuring 750 others. Hezbollah said that it carried out four strikes targeting IDF sites including in Neve Ziv and Beit Hillel with rockets and artillery. Lebanese media reported that Israeli strikes struck Al-Jbeen, Shama, Majdal Zoun, Kfar Kila, Kfar Shiuba, Houla, al-Taybeh, the forest in the vicinity of Kounine and Beit Yahoun, and the outskirts of Yater. The IDF said that it struck Hezbollah sites in Chihine, Tayibe, Blida, Meiss El Jabal, Aitaroun and Kfarkela and a Hezbollah weapons depot in Khiam in these airstrikes. On 19 September, the IDF said that it started carrying out airstrikes against Hezbollah to destroy its capabilities in southern Lebanon while heavy bombing was reported in Deir Qanoun En Nahr.
Sources: en.wikipedia.org
Treatment depends partly on the cause and severity of the disease. There are three main treatment options: radioiodine therapy, medications, and thyroid surgery. Radioiodine therapy involves taking iodine-131 by mouth, which is then concentrated in and destroys the thyroid over weeks to months. The resulting hypothyroidism is treated with synthetic thyroid hormone. Medications such as beta blockers may control the symptoms, and anti-thyroid medications such as methimazole may temporarily help people while other treatments are having an effect. Surgery to remove the thyroid is another option. This may be used in those with very large thyroids or when cancer is a concern. In the United States, hyperthyroidism affects about 1.2% of the population. Worldwide, hyperthyroidism affects 2.5% of adults. It occurs between two and ten times more often in women. Onset is commonly between 20 and 50 years of age. Overall, the disease is more common in those over the age of 60 years. Thyroid disorders affect kidney function markers and may also affect underlying kidney function. Studies suggest that creatinine may decrease in hyperthyroidism and increase in hypothyroidism, whereas cystatin C shows the opposite pattern. Therefore, the effect of thyroid disorders on underlying kidney function remains debated, and it is unclear whether these changes primarily reflect alterations in kidney markers or changes in underlying kidney function.
== See also == Ministry of Inter Provincial Coordination Eighteenth Amendment to the Constitution of Pakistan Federalism in Pakistan Constitution of Pakistan Inter-State Commission Inter-State Council
==== Dairy products ==== Casokinins and lactokinins, breakdown products of casein and whey, occur naturally after ingestion of milk products, especially cultured milk. Their role in blood pressure control is uncertain. The lactotripeptides Val-Pro-Pro and Ile-Pro-Pro produced by the probiotic Lactobacillus helveticus or derived from casein have been shown to have ACE-inhibiting and antihypertensive functions. In one study, L. helveticus PR4 was isolated from Italian cheeses.
A common belief among users is that the smoke of a hookah (waterpipe, narghile) is significantly less dangerous than that from cigarettes. The water moisture induced by the hookah makes the smoke less irritating and may give a false sense of security and reduce concerns about true health effects. Doctors at institutions including the Mayo Clinic have stated that use of hookah can be as detrimental to a person's health as smoking cigarettes, and a study by the World Health Organization also confirmed these findings. Although the smoking effects are similar to a cigarettes, due to the manner in which a hookah is utilized, smoking hookah may potentially absorb a higher amount of toxic substances, compared to cigarette smokers. Each hookah session typically lasts more than 40 minutes, and consists of 50 to 200 inhalations that each range from 0.15 to 0.50 liters of smoke. In an hour-long smoking session of hookah, users consume about 100 to 200 times the smoke of a single cigarette; A study in the Journal of Periodontology found that water pipe smokers were marginally more likely than regular smokers to show signs of gum disease, showing rates 5-fold higher than non-smokers rather than the 3.8-fold risk that regular smokers show. A systematic review on waterpipe smoking and cancer reports that waterpipe smokers had significantly higher, up to six times odds of lung cancer compared to non-smokers. A study on hookah smoking and cancer in Pakistan was published in 2008. Its objective was "to find serum CEA levels in ever/exclusive hookah smokers, i.e.
Sources: en.wikipedia.org
The leading proposal involves sequestration of monomeric actin, which would alter cytoskeletal turnover and cell movement. The actin-binding motif shared with the parent protein is central to that idea. Direct confirmation in whole organisms remains limited.
Very few controlled human studies focus on the seven-residue sequence itself. Most clinical data concern the full-length protein in cardiac or ophthalmic settings. Conclusions drawn for one form should not be assumed to transfer to the other.
Detection normally relies on reversed-phase liquid chromatography paired with mass spectrometry. Chromatographic retention time establishes the expected elution window, and the mass spectrum confirms the molecular ion. Immunoassays exist but can cross-react with related peptides.
No. Thymosin beta-4 is a 43-residue protein, while TB-500 matches only residues 17 to 23 of that chain. The two are related but differ in size, and a method that identifies one does not automatically identify the other.